公开(公告)号：EP0503916A1

公开(公告)日：1992-09-16

申请号：EP92302064.8

申请日：1992-03-11

申请人： IDEC PHARMACEUTICALS CORPORATION

发明人： Chang-Yuil Kang

IPC分类号： G01N33/569 ,  G01N33/68 ,  A61K39/21 ,  C12P21/08

CPC分类号： G01N33/686 ,  A61K39/00 ,  C07K16/1063 ,  C07K16/4225 ,  G01N33/56988

摘要： A novel method is disclosed for selecting antibody reagents for vaccine formulations that are capable of inducing group-neutralizing anti-HIV antibody responses in humans. Also disclosed are anti-idiotype antibodies and hybridoma cell lines capable of producing such antibodies. Further, anti-idiotype antibody-based vaccines and formulations thereof are disclosed. The methods, antibodies, hybridomas and vaccine formulations of the present invention may be useful in the treatment and prevention of HIV infection.

摘要翻译： 公开了一种新型方法，用于选择能诱导人群中中和的抗HIV抗体应答的疫苗制剂的抗体试剂。 还公开了能够产生这种抗体的抗独特型抗体和杂交瘤细胞系。 此外，公开了抗独特型抗体基疫苗及其制剂。 本发明的方法，抗体，杂交瘤和疫苗制剂可用于治疗和预防HIV感染。